Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 16;8(3):47.
doi: 10.3390/brainsci8030047.

Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives

Affiliations
Review

Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives

Giovanni Martinotti et al. Brain Sci. .

Abstract

Hallucinogen Persisting Perception Disorder (HPPD) is a rare, and therefore, poorly understood condition linked to hallucinogenic drugs consumption. The prevalence of this disorder is low; the condition is more often diagnosed in individuals with a history of previous psychological issues or substance misuse, but it can arise in anyone, even after a single exposure to triggering drugs. The aims of the present study are to review all the original studies about HPPD in order to evaluate the following: (1) the possible suggested etiologies; (2) the possible hallucinogens involved in HPPD induction; (3) the clinical features of both HPPD I and II; (4) the possible psychiatric comorbidities; and (5) the available and potential therapeutic strategies. We searched PubMed to identify original studies about psychedelics and Hallucinogen Persisting Perception Disorder (HPPD). Our research yielded a total of 45 papers, which have been analyzed and tabled to provide readers with the most updated and comprehensive literature review about the clinical features and treatment options for HPPD.

Keywords: Hallucinogen Persisting Perception Disorder; LSD; flashbacks; hallucinogenic substances; perceptual disturbances; psychedelics; visual disturbances.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow-chart describing the data collection process.

Similar articles

Cited by

References

    1. Abraham H.D., Aldridge A.M., Gogia P. The psychopharmacology of hallucinogens. Neuropsychopharmacology. 1996;14:285–298. doi: 10.1016/0893-133X(95)00136-2. - DOI - PubMed
    1. Garcia-Romeu A., Kersgaard B., Addy P.H. Clinical Applications of Hallucinogens: A Review. Exp. Clin. Psychopharmacol. 2016;24:229–268. doi: 10.1037/pha0000084. - DOI - PMC - PubMed
    1. Caton C.L.M., Drake R.E., Hasin D.S., Dominguez B., Shrout P.E., Samet S., Schanzer W.B. Differences Between Early-Phase Primary Psychotic Disorders with Concurrent Substance Use and Substance-Induced Psychoses. Arch. Gen. Psychiatry. 2005;62:137–145. doi: 10.1001/archpsyc.62.2.137. - DOI - PubMed
    1. Abraham H.D., Aldridge A.M. Adverse consequences of lysergic acid diethylamide. Addiction. 1993;88:1327–1334. doi: 10.1111/j.1360-0443.1993.tb02018.x. - DOI - PubMed
    1. Inaba D.S., Cohen W.E., Holstein M.E. Physical and Mental Effects of Psychoactive Drugs. 3rd ed. CNS Publications, Inc.; Ashland, OR, USA: 1997. Uppers owners, all arounders.

LinkOut - more resources